Literature DB >> 16455486

p53 ubiquitination: Mdm2 and beyond.

Christopher L Brooks1, Wei Gu.   

Abstract

Although early studies have suggested that the oncoprotein Mdm2 is the primary E3 ubiquitin ligase for the p53 tumor suppressor, an increasing amount of data suggests that p53 ubiquitination and degradation are more complex than once thought. The discoveries of MdmX, HAUSP, ARF, COP1, Pirh2, and ARF-BP1 continue to uncover the multiple facets of this pathway. There is no question that Mdm2 plays a pivotal role in downregulating p53 activities in numerous cellular settings. Nevertheless, growing evidence challenges the conventional view that Mdm2 is essential for p53 turnover.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455486      PMCID: PMC3737769          DOI: 10.1016/j.molcel.2006.01.020

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  94 in total

1.  A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.

Authors:  J M Stommel; N D Marchenko; G S Jimenez; U M Moll; T J Hope; G M Wahl
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

2.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.

Authors:  R Honda; H Tanaka; H Yasuda
Journal:  FEBS Lett       Date:  1997-12-22       Impact factor: 4.124

3.  A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein.

Authors:  R D Everett; M Meredith; A Orr; A Cross; M Kathoria; J Parkinson
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

4.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

5.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

6.  ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

Authors:  Y Zhang; Y Xiong; W G Yarbrough
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

7.  The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Authors:  J Pomerantz; N Schreiber-Agus; N J Liégeois; A Silverman; L Alland; L Chin; J Potes; K Chen; I Orlow; H W Lee; C Cordon-Cardo; R A DePinho
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

Review 8.  Functions of the MDM2 oncoprotein.

Authors:  D A Freedman; L Wu; A J Levine
Journal:  Cell Mol Life Sci       Date:  1999-01       Impact factor: 9.261

9.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Authors:  T Kamijo; J D Weber; G Zambetti; F Zindy; M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

Review 10.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

View more
  342 in total

Review 1.  Using mice to examine p53 functions in cancer, aging, and longevity.

Authors:  Lawrence A Donehower
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11-04       Impact factor: 10.005

2.  Acetylation is indispensable for p53 antiviral activity.

Authors:  Cesar Muñoz-Fontela; Dolores González; Laura Marcos-Villar; Michela Campagna; Pedro Gallego; José González-Santamaría; Daniel Herranz; Wei Gu; Manuel Serrano; Stuart A Aaronson; Carmen Rivas
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

Review 3.  The role of deubiquitinating enzymes in apoptosis.

Authors:  Suresh Ramakrishna; Bharathi Suresh; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2010-08-21       Impact factor: 9.261

4.  Coordination between cell cycle progression and cell fate decision by the p53 and E2F1 pathways in response to DNA damage.

Authors:  Xiao-Peng Zhang; Feng Liu; Wei Wang
Journal:  J Biol Chem       Date:  2010-08-04       Impact factor: 5.157

Review 5.  Posttranslational modification of p53: cooperative integrators of function.

Authors:  David W Meek; Carl W Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

6.  Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; A Aboukameel; Zhiwei Wang; Sanjeev Banerjee; Syed F Zafar; Anton-Scott Goustin; K Almhanna; Dajun Yang; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Curr Cancer Drug Targets       Date:  2010-05       Impact factor: 3.428

7.  Substrate phosphorylation and feedback regulation in JFK-promoted p53 destabilization.

Authors:  Luyang Sun; Lei Shi; Feng Wang; Peiwei Huangyang; Wenzhe Si; Jie Yang; Zhi Yao; Yongfeng Shang
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

8.  Transcriptional regulation of HIV-1 gene expression by p53.

Authors:  Ruma Mukerjee; Pier Paolo Claudio; J Robert Chang; Luis Del Valle; Bassel E Sawaya
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

9.  Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation.

Authors:  Sanjeev Das; Lakshmi Raj; Bo Zhao; Yuki Kimura; Alan Bernstein; Stuart A Aaronson; Sam W Lee
Journal:  Cell       Date:  2007-08-24       Impact factor: 41.582

10.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.